Correction of vaginal biotope in women of reproductive age with genital herpes

Authors

  • В. О. Бенюк National Medical University named after A.A. Bogomolets, Ukraine
  • Л. Д. Ластовецька National Medical University named after O.O. Bogomolets, Ukraine
  • О. А. Щерба National Medical University named after O.O. Bogomolets, Ukraine

DOI:

https://doi.org/10.18370/2309-4117.2015.22.40-46

Keywords:

biotope correction of vagine, genital herpes, Depantol, Lavomax

Abstract

The article studied modern aspects of vaginal biotope and its correction in patients of reproductive age with genital herpes. Results of clinical trials were reviewed. Clinical and laboratory efficiency of complex anti-inflammatory treatment of patients with recurrent genital herpes have proved. It was found that the inclusion of drugs Depantol and Lavomax in the complex therapy reduced the treatment time and the recurrences number of genital herpes

Author Biographies

В. О. Бенюк, National Medical University named after A.A. Bogomolets

MD, Professor, Head

Obstetrics and Gynecology Department number 3

Л. Д. Ластовецька, National Medical University named after O.O. Bogomolets

PhD, associate professor of the Obstetrics and Gynecology Department number 3

О. А. Щерба, National Medical University named after O.O. Bogomolets

Assistant of the Obstetrics and Gynecology Department number 3

References

  1. Beniuk, V.O., Shcherba, O.A., Lastovetska, L.D. “Etiopathogenetical approaches to diagnosis and treatment of candidiasis and herpes vulvovaginitis.” Women's Health, 9(64) (2011): 158–160.
  2. Beniuk, V.A., Lastovetska, L.D., Nikoniuk, T.R., Melnyk, V.V. “Bacterial vaginosis and the modern possibilities of its treatment of women of reproductive age.” Women's Health, 3(69) (2012): 133–138.
  3. Beniuk, V.A. “Experience of the Valtrovir use in patients with recurrent genital herpes.” Women's Health, 1(2009): 193–195.
  4. Krasnopolskiy, V.I., Serova, O.F., Tumanova, V.A., et al. “Effect of infection on the reproductive system of women.” Russian Gazette of Obstetrician-Gynecologist, 5(2004): 26–29.
  5. Nitefor, I.B. “Status of cellular immunity in women with urogenital infections and viral miscarriage.” Bulletin of Scientific Research, Ternopil, 2(2005): 140–141.
  6. Panchenko, L.A. Herpes. Role in human pathology. Antiviral drugs. Kharkiv. Planet Print (2014) 204 p.
  7. Osipova, L.S., Kononenko, I.Y., Solskyi, S.Y., Yurchuk, J.N., Asatova, A.A. “Genital herpes. The course and treatment in modern conditions.” Ukrainian Journal of dermatology, venerology, cosmetology, 3(2012): 5–10.
  8. Strachunskiy, L.S., Kozlov, S.N. Modern Antimicrobial Chemotherapy: Guidelines. Moscow (2002) 436 p.
  9. Bren, L. “Genital herpes: a hidden epidemic.” FDA Consum, 2(36) (2002): 10–16.
  10. Brugha, R. “Genital herpes infection: a review.” Int J Epidemiol, 4(26) (1997): 698–709.
  11. Leitich, H., Bodner-Adler, B., Braunbauer, M., et al. “Bacterial vaginosis as a risk factor for preterm delivery: a meta-analysis.” Am J Obstet Gynecol, 189(2003): 139–147.
  12. Tareeva, T.G., Antipova, I.I., Malinovskaya, V.V., et al. “Immune and interferon status of newborns at viferon treatment of pregnant women with cytomegalovirus and herpes infection.” Russian Immunological Journal, 5(2) (2000): 193–202

Published

2015-04-14

How to Cite

Бенюк, В. О., Ластовецька, Л. Д., & Щерба, О. А. (2015). Correction of vaginal biotope in women of reproductive age with genital herpes. REPRODUCTIVE ENDOCRINOLOGY, (22), 40–46. https://doi.org/10.18370/2309-4117.2015.22.40-46

Issue

Section

Inflammatory diseases